HIGHLIGHTS
- who: Elliot Marseille et al. from the Health Strategies International, Oakland, California, United States of America, University of California have published the Article: The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD, in the Journal: PLOS ONE
- what: MAP provided to patients with severe or extreme, chronic PTSD appears to be cost-saving while delivering substantial clinical benefit.
- how: The authors developed a decision analytic model to portray clinical benefits MAP costs and net medical costs in a cohort of 1000 patients reflecting the age and PTSD . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.